Showing results (251-260 of 454) with videos related to
Sort By:
Pageof 46
The Lancet. Gastroenterology & Hepatology|February 24, 2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trialsMaria Buti, David K Wong, Edward Gane, et al.Journal of Clinical and Translational Hepatology|November 16, 2022
ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV GenotypeLuisa Roade, Mar Riveiro-Barciela, Adriana Palom, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2014
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of EgyptDorothée Obach, Sylvie Deuffic-Burban, Gamal Esmat, et al.Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.Journal of Hepatology|December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II studyLise Retat, Laura Webber, Peter Jepsen, et al.Viruses|July 29, 2023
Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in SpainAdriana Palom, Edurne Almandoz, Antonio Madejón, et al.Pageof 46